Benitec Biopharma (NASDAQ:BNTC) Research Coverage Started at Robert W. Baird

Robert W. Baird began coverage on shares of Benitec Biopharma (NASDAQ:BNTC) in a research report released on Friday, Marketbeat.com reports. The firm issued an outperform rating and a $30.00 price objective on the biotechnology company’s stock.

Several other equities research analysts also recently weighed in on the company. Oppenheimer began coverage on Benitec Biopharma in a report on Wednesday, October 16th. They set an “outperform” rating and a $35.00 price objective on the stock. Guggenheim reissued a “buy” rating and issued a $17.00 price objective on shares of Benitec Biopharma in a research note on Tuesday, December 3rd. Piper Sandler reaffirmed an “overweight” rating on shares of Benitec Biopharma in a research note on Friday, October 18th. Finally, JMP Securities increased their target price on shares of Benitec Biopharma from $16.00 to $18.00 and gave the company a “market outperform” rating in a research report on Monday, October 14th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $23.83.

Benitec Biopharma Price Performance

BNTC stock opened at $11.77 on Friday. The firm has a 50-day moving average price of $10.55 and a 200-day moving average price of $9.29. Benitec Biopharma has a 12 month low of $2.69 and a 12 month high of $13.22.

Insider Transactions at Benitec Biopharma

In related news, Director Suvretta Capital Management, L bought 42,000 shares of Benitec Biopharma stock in a transaction dated Tuesday, December 3rd. The stock was purchased at an average cost of $9.60 per share, with a total value of $403,200.00. Following the transaction, the director now directly owns 7,957,365 shares of the company’s stock, valued at approximately $76,390,704. The trade was a 0.53 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.30% of the company’s stock.

Institutional Trading of Benitec Biopharma

Several hedge funds and other institutional investors have recently modified their holdings of BNTC. Suvretta Capital Management LLC boosted its stake in Benitec Biopharma by 422.0% in the 3rd quarter. Suvretta Capital Management LLC now owns 8,829,053 shares of the biotechnology company’s stock worth $81,139,000 after purchasing an additional 7,137,763 shares during the period. Nantahala Capital Management LLC purchased a new stake in shares of Benitec Biopharma in the second quarter worth about $5,881,000. Simplify Asset Management Inc. boosted its position in shares of Benitec Biopharma by 127.5% in the third quarter. Simplify Asset Management Inc. now owns 116,535 shares of the biotechnology company’s stock valued at $1,071,000 after acquiring an additional 65,319 shares during the period. Geode Capital Management LLC grew its stake in Benitec Biopharma by 31.3% during the third quarter. Geode Capital Management LLC now owns 83,987 shares of the biotechnology company’s stock valued at $772,000 after acquiring an additional 20,012 shares in the last quarter. Finally, Acuta Capital Partners LLC bought a new stake in Benitec Biopharma during the 3rd quarter worth approximately $274,000. Institutional investors own 52.19% of the company’s stock.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.